Last edition
News about
CDSCO Cancels Import Registration of Mediderma Products Over Excess Salicylic Acid
The Central Drugs Standard Control Organisation (CDSCO) has cancelled the import registration of certain skincare products from US-based Mediderma after finding salicylic acid levels far above the permissible limit.
Cambrex Expands Snapdragon Chemistry Facility to Boost Peptide Therapy Manufacturing
Cambrex, a leading global contract development and manufacturing organization (CDMO), announced the expansion of its Snapdragon Chemistry API facility in Waltham, Massachusetts, strengthening its capabilities in peptide drug development and manufacturing.
CuraTeQ Biologics Receives UK MHRA Approval for Trastuzumab Biosimilar Dazublys
CuraTeQ Biologics, a wholly owned step-down subsidiary of Aurobindo Pharma, has obtained marketing authorisation from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for its trastuzumab biosimilar, Dazublys.
Pharmexcil Calls for GST Parity on APIs and Formulations to Boost Pharma Efficiency
The Pharmaceuticals Export Promotion Council of India (Pharmexcil) has called for harmonising GST rates on both active pharmaceutical ingredients (APIs) and finished formulations to streamline compliance and ease financial strain.
Healthium Medtech and C-CAMP Launch Programme to Drive Affordable Surgical Innovations
Healthium Medtech, in collaboration with the Centre for Cellular and Molecular Platforms (C-CAMP), has launched the first cohort of the C-CAMP Healthium Innovations Programme for Surgical Interventions and Medical Technologies in Bengaluru.
MannKind to Acquire scPharmaceuticals, Expanding into Cardiorenal Medicine
MannKind’s acquisition of scPharmaceuticals is expected to be completed in the fourth quarter of 2025.
Esaote, a global leader in medical device manufacturing specializing in ultrasound, dedicated MRI, and healthcare IT, announced that its MyLab A50 and MyLab A70 ultrasound systems have received FDA approval.
US EoE Market Expected to Hit USD 1.19 Billion by 2030, Driven by Next-Gen Therapies
The US market for eosinophilic esophagitis (EoE) is projected to soar from USD 202 million in 2020 to USD 1.19 billion by 2030, reflecting a compound annual growth rate (CAGR) of 19.4 percent, according to GlobalData. This substantial growth is being driven by a transition away from off-label treatments toward FDA-approved, patient-friendly therapies.
GSK Enters Oncology in India with Launch of Jemperli and Zejula for Gynaecological Cancers
GSK has launched its much-awaited advanced therapies Jemperli (dostarlimab) and Zejula (niraparib) in India, reinforcing its commitment to addressing the unmet need for gynaecological cancers in the country.
Eris Lifesciences Secures ANVISA Approval for its Manufacturing Unit in Ahmedabad
Eris Lifesciences has received ANVISA approval for a manufacturing unit at its Ahmedabad campus, paving the way for entry into Brazil, South America’s largest pharmaceutical market.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy